A Phase I/II Trial of HER-2/Neu Pulsed DC1 Vaccine Combined With Trastuzumab for Patients With DCIS

Inclusion Criteria: * Women \>= 18 years. * Ductal carcinoma in situ (DCIS) that express HER-2 3+ on 10% of the DCIS that have not had definitive surgery are diagnosed by core biopsy or NL surgical biopsy with positive margins. * Patients that are ER+ will take anti-estrogen therapy for treatment of their DCIS during vaccinations. * Women of childbearing age with a negative pregnancy test documented prior to enrollment. * Eastern Cooperative Oncology Group (ECOG) Performance Status Score of 0 or 1. * Women of childbearing potential must agree to use a medically acceptable form of birth control during their participation in the study. * Have voluntarily signed a written Informed Consent in accordance with institutional policies after its contents have been fully explained to them. Exclusion Criteria * Pregnant or lactating. * Positive for HIV or hepatitis C at baseline by self-report. * Potential participants with coagulopathies, including thrombocytopenia with platelet count \<75,000, INR\> 1.5 and partial thromboplastin time \> 50 sec * Major cardiac illness MUGA or ECHO \<50% EF. * Pre-existing medical illnesses or medications which might interfere with the study as determined by Principal Investigator (PI).